All those involved with the planning and delivery of this education will disclose all financial relationships in the past 24 months with ineligible companies. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For each financial relationship, disclosure will include the name of the ineligible company and the nature of the financial relationship(s).

John Aucott, MD
Consultant: Pfizer Inc. & Tarsus Pharmaceuticals, Inc.

Adrian Baranchuk, MD, FACC, FRCPC, FCCS, FSIAC
Unrestricted grant, speaker: Medtronic, Abbott & Bayer
Speaker: Pfizer

Edward B. Breitschwerdt, DVM
Founder, Share Holder, Chief Scientific Officer: Galaxy Diagnostics
Consultant: IDEXX Laboratories

Catherine A. Brissette, PhD

Monica E. Embers, PhD
Consultant: Flightpath Biosciences (relationship has ended) & Tarsus Pharmaceuticals

Marna E. Ericson, PhD
Director of Research: TLab, Inc. (relationship has ended)

Brian A. Fallon, MD, MPH

Brandon L. Jutras, PhD

Kim Lewis, PhD
Consultant: Flightpath (relationship has ended)

Kenneth B. Liegner, MD

Ricardo Maggi, PhD
Co-founder, shareholder and the Chief Technical Officer: Galaxy Diagnostics

Elizabeth Maloney, MD
Stock Owner: 3M
President: Partnership for Healing and Health (Company is being dissolved and there has been no business activity since June 2019)

Patricia V Smith, BA

All of the relevant financial relationships listed for these individuals have been mitigated.